INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 299 filers reported holding INTELLIA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 1.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $41 | +78.3% | 1,900 | +35.7% | 0.00% | +33.3% |
Q2 2023 | $23 | +15.0% | 1,400 | +133.3% | 0.00% | +50.0% |
Q1 2023 | $20 | -13.0% | 600 | -40.0% | 0.00% | 0.0% |
Q4 2022 | $23 | -100.0% | 1,000 | -94.4% | 0.00% | -95.1% |
Q3 2022 | $590,000 | +15.9% | 18,000 | +50.0% | 0.04% | +17.1% |
Q2 2022 | $509,000 | -2.5% | 12,000 | +0.9% | 0.04% | +29.6% |
Q1 2022 | $522,000 | +1907.7% | 11,894 | +2873.5% | 0.03% | +2600.0% |
Q4 2021 | $26,000 | -51.9% | 400 | -74.0% | 0.00% | -50.0% |
Q3 2021 | $54,000 | -97.0% | 1,540 | -95.7% | 0.00% | -97.6% |
Q2 2021 | $1,829,000 | +4843.2% | 36,000 | +1252.4% | 0.08% | +2733.3% |
Q2 2018 | $37,000 | -64.4% | 2,662 | -59.4% | 0.00% | -66.7% |
Q1 2018 | $104,000 | +160.0% | 6,562 | -19.0% | 0.01% | +800.0% |
Q4 2017 | $40,000 | -77.0% | 8,098 | -74.7% | 0.00% | -83.3% |
Q3 2017 | $174,000 | +411.8% | 31,976 | +657.5% | 0.01% | +500.0% |
Q2 2017 | $34,000 | – | 4,221 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Discovery Value Fund | 572,950 | $19,990,226 | 5.79% |
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $39,952,225 | 5.34% |
MPM BioImpact LLC | 455,238 | $15,883,254 | 4.12% |
ARK Investment Management | 9,420,782 | $328,691,084 | 2.85% |
Atlas Venture Associates IX, LLC | 10,000 | $348,900 | 1.74% |
Ghisallo Capital Management LLC | 250,000 | $8,722,500 | 1.55% |
Nikko Asset Management Americas, Inc. | 2,976,002 | $103,743,430 | 1.49% |
Prosight Management, LP | 72,116 | $2,516,127 | 1.37% |
Rokos Capital Management LLP | 826,063 | $28,391,785 | 1.24% |
Elmwood Wealth Management, Inc. | 67,899 | $2,368,996 | 1.18% |